Kantonsspital St.Gallen


Hans Rickli, Karin Fink & Susanne Vetsch


Multicenter, randomized, active comparator-controlled, double-blind,
double-dummy, parallel group, dose-finding Phase 2 study to compare
the safety of the oral FXIa inhibitor BAY 2433334 to apixaban in
patients with atrial fibrillation

Primary Safety Endpoint
 composite of International Society on
Thrombosis and Hemostasis (ISTH) major
and clinically relevant non-major bleeding

Intervention over 12 weeks and Safety Follow up after 2 weeks
type of project clinical studies
status completed
start of project 2020
end of project 2021
responsible person Prof. Dr. Hans Rickli, Susanne Vetsch